AstraZeneca Pharma India gets DCGI nod to market cancer drug in India

0
1184

New Delhi, August 18, 2018: Drug firm Pharma today said it has received permission from the of (DCGI) to import and market tablets used for the 

The permission from the DCGI is for (Lynparza) tablets in the strengths of 100 mg and 150 mg, Pharma said in a BSE filing according to business-standard.com

“The import and market permission for is a significant milestone for women in India living with platinum-sensitive relapsed and BRCA-mutated HER-2 negative metastatic breast cancer, which has historically been difficulty-to-treat diseases,” MD Gagan Singh said.

Shares of today closed at Rs 1,710.30 per scrip on BSE, up 1.59 per cent from their previous close.